EPISODE · Aug 13, 2024 · 25 MIN
Symposium | The next wave of immune-based therapies: What you need to know in relapsed/refractory multiple myeloma
from Multiple Myeloma Hub
During the European Hematology Association (EHA) 2024 Hybrid Congress, the Lymphoma Hub and Multiple Myeloma Hub held a joint satellite symposium entitled ‘Sequencing immune-based therapies in B-cell malignancies’. Here the Multiple Myeloma Hub is pleased to share the session: Next wave of immune-based therapies: What you need to know, which focused on relapsed/refractory (R/R) multiple myeloma (MM) and was presented by Krina Patel, MD Anderson Cancer Center, Houston, US. This activity was supported through an educational grant from Bristol Myers Squibb. Hosted on Acast. See acast.com/privacy for more information.
What this episode covers
During the European Hematology Association (EHA) 2024 Hybrid Congress, the Lymphoma Hub and Multiple Myeloma Hub held a joint satellite symposium entitled ‘Sequencing immune-based therapies in B-cell malignancies’. Here the Multiple Myeloma Hub is pleased to share the session: Next wave of immune-based therapies: What you need to know, which focused on relapsed/refractory (R/R) multiple myeloma (MM) and was presented by Krina Patel, MD Anderson Cancer Center, Houston, US. This activity was supported through an educational grant from Bristol Myers Squibb. Hosted on Acast. See acast.com/privacy for more information.
NOW PLAYING
Symposium | The next wave of immune-based therapies: What you need to know in relapsed/refractory multiple myeloma
No transcript for this episode yet
Similar Episodes
Apr 6, 2026 ·25m
Mar 30, 2026 ·27m